Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychosomatics 49:442-446, September-October 2008
doi: 10.1176/appi.psy.49.5.442
© 2008 Academy of Psychosomatic Medicine
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Schaefer, M.
* Articles by Friebe, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Schaefer, M.
* Articles by Friebe, A.
Related Collections
* Depression
* Syndromes Secondary to General Medical Disorders

Case Report

Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFN{alpha}-Associated Mood Disorders

Martin Schaefer, M.D., Jochen Winterer, M.D., Rahul Sarkar, M.D, Ralf Uebelhack, M.D., Leonora Franke, M.D., Andreas Heinz, M.D., and Astrid Friebe, M.D.

Received March 26, 2007; revised July 13, 2007; accepted August 1, 2007. From the Dept. of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Berlin, Germany and the Dept. of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, Essen, Germany. Send correspondence and reprint requests to Martin Schaefer, M.D., Dept. of Psychiatry, Psychotherapy, and Addiction Medicine, Kliniken Essen-Mitte, Henricistr, 92, D-45136 Essen, Germany. e-mail: martin.schaefer{at}charite.de
© 2008 The Academy of Psychosomatic Medicine

BACKGROUND: Interferon-alpha (IFN{alpha})-associated mood disorder is a major complication of treatment for chronic hepatitis C. METHOD: The authors report on three patients infected with chronic hepatitis C showing severe depressive symptoms during or after IFN{alpha} treatment. Because patients had lowered tryptophan blood levels and did not response to antidepressants, they received tryptophan up to a dosage of 1,000 mg/day as mono- or add-on treatment. RESULTS: Tryptophan, used as augmentation or monotherapeutic treatment, led to a significant improvement of depressive symptoms in all three patients. CONCLUSION: A tryptophan deficit seems to be involved in the pathophysiology of persistent mood changes during and after IFN{alpha} treatment.







Get information about faster international access.

Privacy Policy

Copyright © 2008 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org